Screening compounds against the Wolbachia Endosymbiont of filarial nematodes

Status
Completed
Start date
End date
Start stage
Screening
End stage
Screening
Disease
Lymphatic filariasis
Onchocerciasis
Research areas
Drug

Dr. Taylor leaded the Anti-Wolbachia Consortium (A·WOL), whose aim was to develop novel drugs against onchocerciasis and lymphatic filariasis by targeting Wolbachia, the nematodes’ essential endosymbiont. The A·WOL team partnered with AstraZeneca to develop a high-content screening assay for Wolbachia, which was used in screening 1.3 million compounds from AstraZeneca's in-house library that might be re-proposable against onchocerciasis and lymphatic filariasis.